INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • an hour ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • Oct 6, 2026

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.

Zacks Investment Research • Sep 29, 2026

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.” The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrative.

Business Wire • Sep 28, 2026

3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI

Options bears are circling three stocks today, with Aemetis Inc (NASDAQ:AMTX), Acadia Pharmaceuticals Inc (NASDAQ:ACAD), and Resideo Technologies Inc (NYSE:REZI) all seeing puts handily outpace calls.

Schaeffers Research • Sep 28, 2026

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal

Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.

Zacks Investment Research • Sep 25, 2026

Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study

Acadia Pharmaceuticals said on Thursday its experimental drug for psychosis associated with Alzheimer's missed the main goal of ​a mid-stage study testing whether it could reduce hallucinations ‌and delusions in patients with the condition.

Reuters • Sep 24, 2026

Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback

Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study.

Investors Business Daily • Sep 24, 2026

Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data

Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis.  The once-daily 60 mg dose eased hallucinations and delusions more than placebo on the trial's main measure, but the result fell just short of statistical significance at six weeks.

Proactive Investors • Sep 24, 2026

ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer's Psychosis Trial

ACADIA Pharmaceuticals NASDAQ: ACAD reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer's disease psychosis, or ADP. The company said the 60 mg once-daily dose narrowly missed statistical significance on the primary endpoint but showed nominal statistical significance on a key secondary endpoint, while demonstrating a safety and tolerability profile comparable with placebo.

MarketBeat • Sep 24, 2026